Trial Profile
ADaptiVe Biomarker Trial That InformS Evolution of Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs BMS 986156 (Primary) ; Cabiralizumab (Primary) ; Ipilimumab (Primary) ; Linrodostat (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms ADVISE
- Sponsors Bristol-Myers Squibb
- 23 Sep 2022 Status changed from active, no longer recruiting to completed.
- 12 Apr 2022 Planned End Date changed from 16 Apr 2022 to 16 Apr 2024.
- 12 Apr 2022 Planned primary completion date changed from 30 Mar 2022 to 16 Apr 2024.